[Disclosure] Samsung Biologics (207940) – (Correction) Contract Signings for Supply and Sales / 2026-04-10
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has expanded a contract manufacturing agreement originally disclosed in March 2026, increasing the value from KRW 279.6B to KRW 350.0B upon the client’s request. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Future Amended Disclosures Regarding Changes in…